Home-Based Care for Hypertension in Rural South Africa.
Siedner MJ, Magula N, Mazibuko L, Sithole N, Castle A, Nxumalo S, Manyaapelo T, Abrahams-Gessel S, Gareta D, Orne-Gliemann J, Baisley K, Bachmann M, Gaziano TA
Paper source
Home-Based Care for Hypertension in Rural South Africa.
This rigor review was examined and confirmed by Adcurare Editorial · July 7, 2026
How this rating was calculated▸
- IntegrityIntegrity concern−0.5★
- ReportingData & code availability partially met−0.25★
- Data/code availability incomplete
- Data look implausibly clean
This Adcurare Rigor Review uses AI Rigor Reviewers trained on a curated corpus of high-fidelity and retracted papers, with expert supervision and curation. It can still make mistakes; verify each finding against the source before relying on it.
The manuscript describes a well-conducted, rigorously randomized controlled trial of home-based hypertension care in rural South Africa. Its main strengths are a clear design, complete ethics approvals, and thorough reporting of demographic and health variables. The primary weaknesses are missing documentation: no data availability statement, no code sharing, no CONSORT checklist reference, and some under-identification of key resources (drugs, software).
Evaluated as a human interventional RCT. All eight dimensions were applicable. The three independent rigor evaluations largely converged (high agreement on 6 dimensions, moderate divergence on study design and key resources). The statistics verification component checked 4 tests, all consistent; coverage is partial (see component note). No retracted or unresolvable references were found. The copyedit pass flagged minor grammatical/punctuation issues.
12 major claims checked against the paper's own evidence: all adequately supported.
Recomputed 4 tests: 4 consistent, 0 inconsistent, 4 via agent-written checks.
1 integrity concern flagged (0 high).
8 copyedit issues flagged: mostly clarity, consistency, punctuation.
Checked 25 references: 19 verified — 6 not checked.
1 data/code link checked; 1 live.
Registered (1 ID: ClinicalTrials.gov). No reporting guideline cited.
Ready after minor edits. The paper is methodologically sound for submission, but the three 'warn' dimensions (data availability statement, key resources details, and outlier handling/rationale for open-label design) should be addressed before submission to avoid desk rejection or reviewer critique. The copyedit issues should also be cleaned up.
- 1.HIGHdata codeAdd a Data Availability Statement to the end of the manuscript (before References) specifying a managed-access mechanism for de-identified participant data (e.g., via the Africa Health Research Institute repository or on reasonable request with a data-sharing agreement).Many journals require a data availability statement as a condition of submission; its absence is a common cause for return without review.
- 2.HIGHreportingState adherence to the CONSORT 2010 reporting guideline in the Methods section and include a completed CONSORT checklist as supplementary material.A named reporting guideline strengthens manuscript completeness and is expected by many high-impact journals for RCTs.
- 3.HIGHrigorAdd a brief rationale for the open-label design in the Study Design section (e.g., 'blinding of participants and clinic staff was infeasible due to the nature of the intervention and ethical concerns').Describing why blinding was not implemented addresses a standard reviewer expectation and demonstrates methodological awareness.
- 4.HIGHrigorDescribe how outliers in BP measurements were handled in the Statistical Analyses section (e.g., Winsorization, exclusion with criteria, or state that none were excluded and why).Absence of outlier handling is a known reporting gap that reviewers frequently flag.
- 5.HIGHrigorProvide manufacturer, strength/formulation, and national drug code or manufacturer lot information for the three antihypertensive drugs (hydrochlorothiazide, lisinopril, amlodipine) in the Study Arms section.Standard reagents (drugs) should be identified sufficiently for replication; current reporting is inadequate.
- 6.HIGHrigorAdd version numbers and RRIDs for the BP devices (Omron Digital M3, BlipCare) and the mobile health application (iMarketing Consultants) in the Study Arms section.Key resources should be traceable; version/identifier details support reproducibility.
- 7.HIGHstatisticsName the statistical software package and version used for all analyses (e.g., Stata 17, R 4.3.1) in the Statistical Analyses section.Reporting the software improves reproducibility and is a standard expectation for rigorous statistical reporting.
- 8.HIGHrigorIn the Background section, explicitly discuss how the current study addresses the limitations of prior research on home-based hypertension care in low-resource settings.All three reviewers noted that limitations of prior work are not explicitly addressed, which weakens the scientific premise narrative.
- 9.MEDIUMreportingProvide a permanent DOI link (e.g., on Zenodo, ClinicalTrials.gov) for the study protocol and statistical analysis plan in the Methods section rather than just referencing 'supplementary material'.A permanent repository link ensures the protocol remains accessible and citable.
- 10.MEDIUMcopyeditFix the comma-to-decimal error in Results, paragraph 2: change '−11,1' to '−11.1'.Using a comma as a decimal separator is inconsistent with standard English-language scientific writing and could confuse readers.
- 11.MEDIUMcopyeditIn Methods, Study Arms, change the period after 'M3' to a comma: 'Omron Digital M3, Kyoto, Japan'.Minor punctuation error.
- 12.MEDIUMcopyeditIn Methods, Statistical Analyses, change 'we fit logistic regression models' to 'we fitted logistic regression models' for grammatical consistency in past tense.Consistent verb tense improves readability.
- 13.LOWcopyeditIn the Abstract, remove the redundant second '(eCHW+ arm)' after 'transmitted readings automatically'.Eliminates redundancy and matches the concise style of the other arm descriptions.
- 14.LOWcopyeditIn Methods, Sample Size, rephrase 'allowing for 20% loss to follow-up' to 'assuming a 20% loss to follow-up' for clarity.Minor wording clarification.
Adcurare assesses methodological rigor, not the importance of the findings. See how we evaluate →